Helsinn – the Swiss pharmaceutical group focused on building quality cancer care and rare disease products – is pleased to announce the appointment of Mary Lynne Hedley as a new member of its board of directors, effective
Helsinn – the Swiss pharmaceutical group focused on building quality cancer care and rare disease products – is pleased to announce the appointment of Mary Lynne Hedley as a new member of its board of directors, effective